Neko Health sells a one-hour, in-clinic preventive health scan that combines contactless skin and body imaging, cardiovascular assessment, on-site blood testing of 50-plus biomarkers, and biometric checks such as grip strength and eye pressure. The scan uses no ionizing radiation — it is not an MRI or CT scan — and relies on proprietary sensors the company designs and manufactures in-house, used to collect several kinds of measurements during one appointment.

A member books an appointment at a Neko clinic and spends roughly 30 minutes in the measurement phase. Contactless imaging captures a baseline of moles and skin markings alongside body composition data including visceral and body fat. Cardiovascular sensors record the heart's electrical activity and arterial health, including microcirculation at the feet. Blood is drawn and processed on-site, covering nine health areas — heart health, metabolism, immunity, inflammation, and others — with same-visit results.

The remaining 30 minutes are spent with a clinician who reviews all findings together, explains results in context, and delivers a personalized action plan. If something requires further attention, Neko offers in-house follow-up where possible, including ultrasounds and echocardiograms, and refers members to external specialists. In New York, referral partners include Mount Sinai Health System, Columbia University Irving Medical Center, Schweiger Dermatology, and General Medicine. A dermatology network reviews flagged moles.

Neko recently added wearable data integration, allowing clinicians to review sleep, movement, and recovery data from connected devices alongside scan results. The scan creates a longitudinal baseline: members who return annually can compare skin, blood, and cardiovascular data visit to visit. The company reports that 75% of members book and prepay their next scan at the end of their first appointment, and 80% book a third after their second — these are advance bookings, rather than measured completed annual return visits.

Neko charges consumers for each scan, with its U.S. service priced at $499. The U.S. scan is HSA and FSA eligible. Members pay out of pocket for the scan. The model is a one-off or annually repeated transaction rather than an automatic subscription.

On the cost side, Neko bears fixed clinic rent, proprietary device depreciation and R&D, and variable costs including clinical staff time, blood-testing consumables, and referral-care coordination. The company's vertical integration — designing hardware, software, and clinical protocols in-house — is intended to give it control over throughput and unit economics, and its next-generation devices are engineered to increase automation and free clinical staff to focus on member consultations. Whether this translates into proven positive unit margins at scale is not publicly disclosed.

Advance bookings can help clinics plan capacity, but actual completed return visits and the cost of delivering follow-up care remain important to the economics. Clinic capacity utilization — how many scans a location can run per day and how quickly clinicians can review results — helps determine how much business a site can support.

Neko Health occupies a distinct position in the emerging consumer preventive-health market by combining multi-modal sensor data, blood biomarkers, and a same-visit clinician consultation in a single vertically integrated experience. Its closest competitors approach prevention from different modalities and price points, and the broader competitive set includes the existing primary-care system and its insurance-funded annual physicals.

Prenuvo and Ezra offer MRI-based screening, using a different measurement approach from Neko's combination of skin imaging, cardiovascular measurements and blood testing. MRI itself also avoids ionizing radiation, so radiation exposure does not distinguish Neko from those services. Consumers comparing the offerings must consider which measurements they want and how findings connect to clinical follow-up, rather than treating the scans as interchangeable.

Function Health offers a lab-focused membership built around blood testing through an existing laboratory network. Neko adds proprietary in-person measurements and an immediate clinician discussion, while taking on the cost and capacity constraints of its own clinics. The competing approaches differ in how much of the experience requires dedicated physical infrastructure.

The most common alternative to any of these services is a standard annual physical covered by health insurance, supplemented by specialist referrals. Neko does not replace primary care and explicitly refers members to external physicians when needed. The risk for Neko is that consumers who already have a trusted doctor and insurance-funded preventive visits may see $499 as duplicative rather than additive, particularly outside the wellness-forward demographic that drives early adoption.

Neko's current addressable market is self-pay consumers in three countries willing to spend several hundred dollars annually on a preventive scan. Expanding beyond this base requires reaching new buyer types, entering new geographies with different regulatory and payment structures, and validating additional clinical applications for its measurement technology.

The September 2026 opening of Neko's SoHo clinic — with 25,000 people on the New York waitlist alone — is the company's first entry into the world's largest consumer health-spending market. Its $499 price and HSA/FSA eligibility create a concrete self-pay offering, although a waitlist does not establish how many people will complete paid scans. Additional New York locations and a Miami clinic are expected to follow, with Washington, D.C. and San Francisco also planned. Each new U.S. city represents incremental TAM without requiring a new product, though it does require local clinical licensing, referral-network partnerships, and real-estate buildout.

Employer-funded preventive benefits could provide a different buyer from the individual consumer. If Neko were to offer corporate packages or integrate into employer wellness programs, it could access a buyer with a larger per-employee budget than individual consumers and a recurring annual purchase cycle. No employer contracts have been announced, and the company would need to demonstrate measurable health-outcome improvements to justify corporate procurement, but the fixed-price, time-efficient format is well suited to an employer benefit.

Neko is already running three clinical studies in Sweden — two sub-studies within the large-scale SCAPIS 2 cardiovascular and pulmonary research program and a diabetes-focused MIND study — investigating microcirculation, vascular aging, and early disease mechanisms using its proprietary sensor data. If these studies produce validated clinical findings, Neko could potentially develop technology partnerships with health systems pursuing population-level prevention. This path would require navigating medical-device regulatory approvals, patient-data privacy frameworks, and peer-reviewed clinical validation, and the studies do not establish an existing technology-licensing business.

Clinical validity and false positives: Neko's scan covers a broad surface area of health signals but is not a comprehensive diagnostic or cancer screen, and the company states it does not replace standard care. A high rate of flagged findings that turn out to be benign could erode member trust and generate unnecessary downstream medical costs, while missed conditions could create liability exposure.

Clinic capital intensity and labor constraints: Each new location requires proprietary hardware, leased real estate, and licensed clinicians — a capital- and labor-intensive expansion model that contrasts with software-like margins. Expansion depends on recruiting qualified clinical staff in each market and achieving sufficient utilization per site to cover fixed costs.

Global regulatory and privacy complexity: Regulatory status varies by device and market, so clearance for one component or geography does not establish approval of the entire service everywhere. Medical-device requirements, clinical licensing and protection of sensitive health information could slow expansion or require costly changes.